[go: up one dir, main page]

CO6660508A2 - Sistema polimérico para suministrar una solución no viscosa a base de prostaglandina, sin conservadores - Google Patents

Sistema polimérico para suministrar una solución no viscosa a base de prostaglandina, sin conservadores

Info

Publication number
CO6660508A2
CO6660508A2 CO12234226A CO12234226A CO6660508A2 CO 6660508 A2 CO6660508 A2 CO 6660508A2 CO 12234226 A CO12234226 A CO 12234226A CO 12234226 A CO12234226 A CO 12234226A CO 6660508 A2 CO6660508 A2 CO 6660508A2
Authority
CO
Colombia
Prior art keywords
prostaglandin
solution
preservatives
solution based
viscous solution
Prior art date
Application number
CO12234226A
Other languages
English (en)
Inventor
Fabrice Mercier
Original Assignee
Thea Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43064334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6660508(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thea Lab filed Critical Thea Lab
Publication of CO6660508A2 publication Critical patent/CO6660508A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una solución oftálmica, cuyo ingrediente activo incluye por lo menos una prostaglandina; dicha solución no contiene agentes antimicrobianos, notablemente del tipo de amonio cuaternario (tales como cloruro de benzalconio [BAK]). Esta invención también se refiere a un sistema polimérico de suministro, que ha sido desarrollado para permitir que la solución de prostaglandina sea tan efectiva como una solución que contiene BAK, pero sin sus desventajas, desde el punto de vista toxicológico y alergénico.
CO12234226A 2010-06-29 2012-12-27 Sistema polimérico para suministrar una solución no viscosa a base de prostaglandina, sin conservadores CO6660508A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35969910P 2010-06-29 2010-06-29
FR1055236A FR2961694B1 (fr) 2010-06-29 2010-06-29 Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur

Publications (1)

Publication Number Publication Date
CO6660508A2 true CO6660508A2 (es) 2013-04-30

Family

ID=43064334

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12234226A CO6660508A2 (es) 2010-06-29 2012-12-27 Sistema polimérico para suministrar una solución no viscosa a base de prostaglandina, sin conservadores

Country Status (27)

Country Link
US (2) US20110319487A1 (es)
EP (1) EP2588078B1 (es)
JP (2) JP5657789B2 (es)
KR (1) KR101809713B1 (es)
CN (2) CN102958509B (es)
AU (1) AU2011273549B2 (es)
BR (1) BR112012033435B1 (es)
CA (1) CA2802816C (es)
CL (1) CL2012003684A1 (es)
CO (1) CO6660508A2 (es)
DK (1) DK2588078T3 (es)
EA (1) EA025026B1 (es)
ES (1) ES2486793T3 (es)
FR (1) FR2961694B1 (es)
HK (2) HK1178446A1 (es)
HR (1) HRP20140631T1 (es)
MA (1) MA34324B1 (es)
MX (1) MX2012014503A (es)
PL (1) PL2588078T3 (es)
PT (1) PT2588078E (es)
RS (1) RS53417B (es)
SG (1) SG186361A1 (es)
SI (1) SI2588078T1 (es)
SM (1) SMT201400098B (es)
TN (1) TN2012000588A1 (es)
UA (1) UA107718C2 (es)
WO (1) WO2012001009A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553827T3 (es) 2009-05-01 2015-12-14 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedad
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
KR102210895B1 (ko) * 2013-03-08 2021-02-02 폴리액티바 피티와이 리미티드 생리활성 물질의 전달을 위한 폴리머 결합체
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
EP3057575B1 (en) 2013-10-15 2021-09-08 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
GR1008330B (el) * 2013-10-17 2014-10-20 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση εχoν βελτιωμενες φυσικες ιδιοτητες και ογκο σταγονας
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
PL3103439T3 (pl) * 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
IT201600103956A1 (it) * 2016-10-17 2018-04-17 Omikron Italia S R L Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
CA3054084A1 (en) 2017-03-14 2018-09-20 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2018236158A1 (ko) * 2017-06-22 2018-12-27 연성정밀화학(주) 녹내장 치료용 점안 조성물
EP3593788B1 (en) * 2018-07-12 2020-10-28 Nicox S.A. Ophthalmic compositions containing a nitric oxide releasing prostamide
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
EP3849555A4 (en) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN110711175A (zh) * 2019-11-12 2020-01-21 南京华盖制药有限公司 一种他氟前列素滴眼剂及其制备方法
US11857538B2 (en) * 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
US11857539B2 (en) 2022-02-09 2024-01-02 Somerset Therapeutics, Llc Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10021A (en) * 1853-09-13 Screw-eastemtito- for boots and shoes
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
NZ507026A (en) * 1998-04-02 2003-09-26 Novartis Ag Method for stabilizing pharmaceutical compositions by special use of an antioxidant
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
MX2010003364A (es) * 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
BRPI0818459A2 (pt) * 2007-10-16 2015-04-14 Sun Pharma Advanced Res Co Ltd Composição farmacêutica adequada para uso oftálmico.
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur

Also Published As

Publication number Publication date
SMT201400098B (it) 2014-09-08
HK1201464A1 (en) 2015-09-04
JP2013532159A (ja) 2013-08-15
KR20130112728A (ko) 2013-10-14
TN2012000588A1 (fr) 2014-04-01
US20120322871A1 (en) 2012-12-20
MA34324B1 (fr) 2013-06-01
CN104274396A (zh) 2015-01-14
EP2588078A1 (fr) 2013-05-08
EA201291307A1 (ru) 2013-05-30
CA2802816A1 (fr) 2012-01-05
JP2015038099A (ja) 2015-02-26
JP5877885B2 (ja) 2016-03-08
JP5657789B2 (ja) 2015-01-21
CA2802816C (fr) 2015-05-12
MX2012014503A (es) 2013-01-29
HK1178446A1 (en) 2013-09-13
EA025026B1 (ru) 2016-11-30
DK2588078T3 (da) 2014-08-18
EP2588078B1 (fr) 2014-05-14
PL2588078T3 (pl) 2014-09-30
PT2588078E (pt) 2014-07-16
CL2012003684A1 (es) 2013-03-08
UA107718C2 (en) 2015-02-10
SG186361A1 (en) 2013-01-30
CN104274396B (zh) 2017-07-04
BR112012033435A2 (pt) 2016-11-22
SI2588078T1 (sl) 2014-09-30
US8637054B2 (en) 2014-01-28
WO2012001009A1 (fr) 2012-01-05
AU2011273549B2 (en) 2013-06-27
RS53417B (en) 2014-12-31
HRP20140631T1 (hr) 2014-09-26
CN102958509A (zh) 2013-03-06
CN102958509B (zh) 2015-01-21
KR101809713B1 (ko) 2017-12-15
BR112012033435B1 (pt) 2022-03-29
ES2486793T3 (es) 2014-08-19
US20110319487A1 (en) 2011-12-29
AU2011273549A1 (en) 2013-01-10
FR2961694A1 (fr) 2011-12-30
FR2961694B1 (fr) 2013-01-25

Similar Documents

Publication Publication Date Title
CO6660508A2 (es) Sistema polimérico para suministrar una solución no viscosa a base de prostaglandina, sin conservadores
DOP2018000085A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de actuación sistémica y sus usos
CY1121402T1 (el) Παρασιτοκτονες συνθεσεις οι οποιες περιλαμβανουν εναν δραστικο παραγοντα ισοξαζολινης, μεθοδοι και χρησεις αυτων
MX2016013794A (es) Tapas antimicrobianas para conectadores medicos.
CR20120483A (es) Composiciones parasiticidas que comprenden agentes activos múltiples, métodos y usos de los mismos
CL2014002700A1 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
ATE493970T1 (de) Konservierungsmittelfreie augenlösung auf prostaglandin-basis
CO2017010065A2 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina
CL2017002164A1 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
UY34189A (es) Mezclas fungicidas que comprenden isoxazol y otro ingrediente activo.
BR112017025994A2 (pt) formulações de oxima de ciclo-hexanodiona estabilizadas com tensoativo
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
UA76167U (xx) Дезінфікуючий засіб "фаг"
UA108358U (uk) Застосування похідних 2-амінооцтової кислоти як засобів протимікробної дії

Legal Events

Date Code Title Description
FC Application refused